Endostar treatment of lung cancer in general is that the treatment of liver cancer equally effective? Endostar you have health insurance?
Endostar treatment of lung cancer in general is that the treatment of liver cancer equally effective? Endostar you have health insurance? Who its prospectus?
If the treatment of liver cancer are equally effective, then I want to buy, who knows that can buy genuine?
Answer:
Endostar for angiostatin new class of biological products, with broad-spectrum anti-angiogenesis activity. Its mechanism is by inhibiting the formation of vascular endothelial cell migration and inhibit tumor angiogenesis
Generation, blocking tumor nutrition supply, and thus inhibit tumor proliferation or transfer. It can block endothelial on ��5��1 integrin (Integrin, which is angiogenesis in cell adhesion molecule) [1,2], and endothelial cells by blocking selectin show its anti-angiogenesis activity; also can block the metal 2,9 and 13 protease activity, is multiple angiogenesis inhibitors. In vitro experiments show that Endostar on human microvascular endothelial cell line HHEC migration, Tube formation inhibition, and could inhibit the chick chorioallantoic membrane angiogenesis, prompted Endostar in vitro has a certain role in anti-angiogenesis. In addition, the Endostar on human lung adenocarcinoma cell SPC2A4 a certain degree of growth inhibition. In vivo experiments show that Endostar mouse tumor model shows the broad-spectrum anti-tumor activity (S180 sarcoma, H22 liver cancer), and anti-human tumor xenograft (SPC2A4 lung adenocarcinoma, SGC7901 gastric cancer, Hela cervical cancer, SMMC27721 and Bel7402 HCC) activity. It is easy to Sin Tong Benevolent Society, in Beijing, I saw large pharmacy information, you can go and see. Now it seems Endostar health insurance or does not belong to the scope, you can easily Sin Tong Benevolent Society, went to Beijing to see large pharmacy drugs, which have to sell the drug.
This is the manual: [common name] recombinant human endostatin in2jection, recombinant human endostatin injection
[Commodity name] Endostar, Endostar
[Characters] colorless liquid clarity, PH 5.5 �� 0.5.
[Pharmaco] product is angiostatin new class of biological products, with broad-spectrum anti-angiogenesis activity. Its mechanism is by inhibiting the formation of vascular endothelial cell migration and inhibit tumor angiogenesis, tumor blocking the nutritional supply, and thus inhibit tumor proliferation or transfer. It can block endothelial on ��5��1 integrin (Integrin, which is angiogenesis in cell adhesion molecule) [1,2], and endothelial cells by blocking selectin show its anti-angiogenesis activity; also can block the metal 2,9 and 13 protease activity, is multiple angiogenesis inhibitors. In vitro experiments showed that the products of human microvascular endothelial cell line HEC migration, Tube formation inhibition, and could inhibit the chick chorioallantoic membrane angiogenesis, suggesting that the goods have a certain role in anti-angiogenesis in vitro. In addition, the commodities of human lung adenocarcinoma cells have a certain SPC2A4 growth inhibition. In vivo indicate that the goods on the mouse tumor model shows the broad-spectrum anti-tumor activity (S180 sarcoma, H22 liver cancer), and anti-human tumor xenograft (SPC2A4 lung adenocarcinoma, SGC7901 gastric cancer, Hela cervical cancer, SMMC27721 and Bel7402 HCC) activity.
Intravenous narcotic dogs to the goods were high, medium and low-dose 115,3,6 mg? Kg-1 (214 �� 104418 �� 104916 �� 104 U? Kg-1), the results of blood pressure, respiration and ECG indicators in the former administration, After no significant change in the number of activities in mice autonomy not affected. Monkey long-term toxicity tests showed that continuous intravenous administration of the goods 3,10,30 mg? Kg-1? D-1 (418 �� 104116 �� 105418 �� 105 U? Kg-1? D-1) three-dose group were 9 months, the results of each group signs monkeys, the appearance of acts, activities and so no obvious abnormal reaction. Weight and food intake, hematology, blood chemistry, ECG and urine test results are in the normal range, suggesting the liver and renal function had no significant damage. In addition, protein, fat, carbohydrate metabolism in normal. Histopathological results showed that continuous intravenous administration of 9 months, 32 monkeys organ coefficient was no significant difference in each group and no drug-dose-related abnormalities, suggesting that the goods at less than 30mg (418 �� 105 U)? kg-1? d-1 dose range of continuous intravenous administration of 9 months, no significant toxicity for the safe dose [3].
[Pharmacokinetics] in healthy volunteers a single intravenous infusion of 30 m in the goods within 30mg (418 �� 105 U) and 60mg (916 �� 105 U)? M-2 and 120min with intravenous infusion of 120 mg (1912 �� 105 U) and 210 m (3316 �� 105 U)? m-2 (infusion rates of 1,2 and 11175 mg? m-2? m in-1), its terminal elimination half-life (t1 / 2) about 10 h, systemic clearance (Cls) for 218 L? h-1? m-2 or so. This product in the 30 ~ 120mg? M-2 (418 �� 105 ~ 1912 �� 105 U? M-2) dose range was similar to the body in normal linear pharmacokinetics can be used linear models to predict the different doses, infusion rates and plasma concentration time. Drip rate, time and total dose may affect the goods AUC and peak concentration levels [4]. Cancer patients within 2 h daily intravenous the goods, for 28 d-time curve between individuals vary, Gu concentration increased with the administration continued the trend of increase, the total number of doses and infusion can affect the level of concentration and Cmin . One-time subcutaneous injection to mice of the goods pharmacokinetic studies have shown that bioavailability was 100%, in normal mice after intravenous administration of urinary tract and drainage of the highest drug concentration, kidney, urinary, lung and liver were higher than plasma, muscle, fat and brain concentration of the lowest, mainly from the urine excretion. Intravenous injection of tumor-bearing mice after the body of the goods distribution and similar to normal mice, tumor tissue distribution is not high, with the muscle and adipose tissue concentration similar.
[Indication] of the goods and cisplatin plus vinorelbine chemotherapy (NP) program for the treatment of newly diagnosed or re-governance �� / �� non-small cell lung cancer patients [5].
[Adverse Drug Reaction] This product is common adverse reactions (1% incidence rate <10%) major cardiac adverse reactions, the main symptoms of sinus tachycardia, mild ST2T changes, atrioventricular block, atrial premature beats , occasional premature ventricular contractions and so on, is commonly found in coronary heart disease, high blood pressure in patients with a history. Clinical application of the recommendations in the course of regular testing electrocardiogram, heart of the adverse reactions in patients with ECG, the history of serious heart disease should not control under the guidance of the doctor's advice to use. Rare (011% <incidence rate <1%) have a digestive reaction (occasional nausea, vomiting, diarrhea, abnormal liver function, including asymptomatic elevated transaminases, jaundice 2 mainly light to moderate, a rare severe ), skin allergies (expressed as full-body rash, accompanied by itching). A small number of patients with early drug use may be mild fatigue, chest tightness, palpitation, the vast majority of adverse reactions by the symptomatic treatment can be improved, does not affect the continued drug use, very few cases due to the persistence of these symptoms stop medication. Fever, weakness mostly mild to moderate [3].
[Usage and dosage] separate delivery: clinical use of the goods will be adding 250 ~ 500 mL physiological sodium chloride solution, the uniform infusion, time 3 ~ 4 h. NP chemotherapy and joint administration: to give the goods 715mg? M-2 (112 �� 105 U? M-2), qd, for delivery 14 d, rest 1 week and continue to the next cycle of treatment. Will normally be carried out 2 to 4 cycles. Recommended tolerance in patients with clinical cases may be appropriate to extend the use of time.
[Note] heart, kidney dysfunction, allergy or proteins have allergy biological products used with caution. Or a history of serious heart disease, including: the recorded history of congestive heart failure, high-risk sexual beyond the control of arrhythmia, angina need drug treatment, clinical diagnosis of heart valve disease, a serious history of myocardial infarction and patients with resistant hypertension used with caution. Clinical use of the process should be conducted on a regular basis electrocardiogram detection, heart adverse reactions should be conducted ECG.
��Drug interactions��
Not systematically studied this Commodities interaction with other drugs. In clinical use, should pay attention to and may not affect the value of goods or other drugs mixed-use solution.
[Clinical evaluation] in April 2003 -2004 year in June, by the Chinese Academy of Medical Sciences Cancer Hospital to take the lead, organizing large-scale integrated 24 national hospitals and specialist hospitals for the goods were randomized, double-blind, placebo-controlled parallel multi-center clinical trials, to verify the goods plus vinorelbine and cisplatin (NP program) in advanced non-small cell lung cancer (NSCLC) in the role. Selected cases by pathology and / or cytology confirmed to �� / �� NSCLC initial treatment period, or re-treated patients, a total of 493 cases, 486 cases can be evaluators. The results of the pilot group and the control group the total effective rate (RR) were 3514% and 1915% (P = 01000 3), the overall clinical benefit rate (CBP) to 7313 percent and 6410 percent, the overall median time to tumor progression (TTP) respectively on 613 and 316 months (P = 01000 0). Of untreated patients, 2 RR were 40% and 2319% (P = 01003), CBP and 7615 percent respectively, 6515% (P = 01023), the median TTP was 616 months and 317 months (P = 010,000); on the re-treated patients, 2 RR were 2319% and 15% (P = 01034), CBP and 6512 percent respectively, 6117% (P = 0168), the median TTP were on 517 and 312 months (P = 01000 2). Clinical symptoms of the test group remission rate is slightly higher than the control group, but no significant difference (P> 0105); the experimental group after treatment QOL score compared with the control group improved (P = 01015 5). In 493 cases of adverse reactions to the evaluation of patients, a total of five cases of serious adverse reactions occurred in the death of three cases in which the experimental group (3 / 326, 0192%), the cause of death were severe abdominal pain and bone marrow suppression caused by severe infection; the control group There are two cases (2 / 167, 01012%), cause of death was severe infection and respiratory failure, the mortality rate of 2 groups had no statistical difference (P = 1100), and other treatment-related adverse reactions (including lower extremity edema, rash , angina, cardiac arrhythmia, abnormal electrocardiogram) the incidence of Group 2 and 5183 percent respectively, 4119%, no statistical difference (P = 0153). 10 percent greater than the incidence of adverse reactions include neutropenia, anemia, thrombocytopenia, nausea, vomiting, constipation, hair loss, fatigue, pain, no statistical difference.
[Specifications and packaging] Injection: 15 mg / 3 mL / branch (214 �� 105 U / support)
[Storage conditions] in 2 ~ 8 �� and dark storage and transport.
Validity period of the tentative 8 months.
